224 related articles for article (PubMed ID: 22891797)
1. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial.
Berk M; Dean OM; Cotton SM; Gama CS; Kapczinski F; Fernandes B; Kohlmann K; Jeavons S; Hewitt K; Moss K; Allwang C; Schapkaitz I; Cobb H; Bush AI; Dodd S; Malhi GS
BMC Med; 2012 Aug; 10():91. PubMed ID: 22891797
[TBL] [Abstract][Full Text] [Related]
2. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial.
Berk M; Copolov DL; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Bush AI
Biol Psychiatry; 2008 Sep; 64(6):468-75. PubMed ID: 18534556
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study.
Ellegaard PK; Licht RW; Nielsen RE; Dean OM; Berk M; Poulsen HE; Mohebbi M; Nielsen CT
J Affect Disord; 2019 Feb; 245():1043-1051. PubMed ID: 30699846
[TBL] [Abstract][Full Text] [Related]
4. A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression.
Bauer IE; Green C; Colpo GD; Teixeira AL; Selvaraj S; Durkin K; Zunta-Soares GB; Soares JC
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549489
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
Berk M; Dean O; Cotton SM; Gama CS; Kapczinski F; Fernandes BS; Kohlmann K; Jeavons S; Hewitt K; Allwang C; Cobb H; Bush AI; Schapkaitz I; Dodd S; Malhi GS
J Affect Disord; 2011 Dec; 135(1-3):389-94. PubMed ID: 21719110
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial.
Kauer-Sant'Anna M; Frey BN; Fijtman A; Loredo-Souza AC; Dargél AA; Pfaffenseller B; Wollenhaupt-Aguiar B; Gazalle FK; Colpo GD; Passos IC; Bücker J; Walz JC; Jansen K; Ceresér KM; Bürke Bridi KP; Dos Santos Sória L; Kunz M; Pinho M; Kapczinski NS; Goi PD; Magalhães PV; Reckziegel R; Burque RK; de Azevedo Cardoso T; Kapczinski F
J Psychopharmacol; 2019 Apr; 33(4):502-510. PubMed ID: 30835152
[TBL] [Abstract][Full Text] [Related]
8. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.
Dean OM; Turner A; Malhi GS; Ng C; Cotton SM; Dodd S; Sarris J; Samuni Y; Tanious M; Dowling N; Waterdrinker A; Smith D; Berk M
Braz J Psychiatry; 2015; 37(1):3-12. PubMed ID: 25295681
[TBL] [Abstract][Full Text] [Related]
9. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.
Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA
BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
Tohen M; Calabrese JR; Sachs GS; Banov MD; Detke HC; Risser R; Baker RW; Chou JC; Bowden CL
Am J Psychiatry; 2006 Feb; 163(2):247-56. PubMed ID: 16449478
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
[TBL] [Abstract][Full Text] [Related]
13. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Yatham LN; Arumugham SS; Kesavan M; Ramachandran K; Murthy NS; Saraf G; Ouyang Y; Bond DJ; Schaffer A; Ravindran A; Ravindran N; Frey BN; Daigneault A; Beaulieu S; Lam RW; Kondapuram N; Reddy MS; Bhandary RP; Ashok MV; Ha K; Ahn YM; Milev R; Wong H; Reddy YCJ;
N Engl J Med; 2023 Aug; 389(5):430-440. PubMed ID: 37530824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA
J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554
[TBL] [Abstract][Full Text] [Related]
16. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A; Maloney K; Muralidharan A; Ruf B; Blumberg HP; Sanacora G; Lorberg B; Pittman B; Bhagwagar Z
J Clin Psychiatry; 2011 Jun; 72(6):744-50. PubMed ID: 21034692
[TBL] [Abstract][Full Text] [Related]
18. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM
Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312
[TBL] [Abstract][Full Text] [Related]
19. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial.
Ghaemi SN; Whitham EA; Vohringer PA; Barroilhet SA; Amerio A; Sverdlov O; Patkar AA
J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434956
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
Calabrese JR; Keck PE; Macfadden W; Minkwitz M; Ketter TA; Weisler RH; Cutler AJ; McCoy R; Wilson E; Mullen J
Am J Psychiatry; 2005 Jul; 162(7):1351-60. PubMed ID: 15994719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
